Summary: “Treatment with psychedelic drugs represents a paradigm shift in the approach to mental health,” explains author Erica Rex in a Scientific American article where she shares her experience as a participant in a clinical trial of psilocybin for cancer-related depression. From this experience, Rex examines the differences between the therapeutic process in traditional psychotherapy versus psychedelic therapy and explores the potential for psychedelic-assisted therapies, including MDMA and psilocybin, to treat a variety of mental health conditions.
Originally appearing here.